Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$564,000.

  • Foghorn Therapeutics' Change in Accured Expenses fell 76.72% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 175.47%. This contributed to the annual value of -$564,000 for FY2024, which is 68.61% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Change in Accured Expenses stood at -$564,000 for FY2024, which was up 68.61% from -$1.8 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Change in Accured Expenses high stood at $3.2 million for FY2020, and its period low was -$1.8 million during FY2023.
  • In the last 3 years, Foghorn Therapeutics' Change in Accured Expenses had a median value of -$564,000 in 2024 and averaged -$306,667.
  • As far as peak fluctuations go, Foghorn Therapeutics' Change in Accured Expenses crashed by 224.71% in 2023, and later skyrocketed by 68.61% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Change in Accured Expenses (Yearly) stood at $3.2 million in 2020, then fell by 16.94% to $2.7 million in 2021, then tumbled by 45.68% to $1.4 million in 2022, then slumped by 224.71% to -$1.8 million in 2023, then skyrocketed by 68.61% to -$564,000 in 2024.